Search
Returning search results with filters:
Remove filter for
Category: Drugs
Remove filter for
Issue: Health products
Clear all
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.
Displaying 1 - 7 of 7 items.
Authorization of Casirivimab and Imdevimab with English-only Labels for Use in Relation to the COVID-19 Pandemic
… Sale and Advertising of Drugs for Use in Relation to COVID-19 . Casirivimab and imdevimab, to be administered together, … treatment of mild to moderate coronavirus disease 2019 (COVID-19), confirmed by direct SARS-CoV-2 viral testing, in …
AlertHealth professional risk communication | 2021-07-30
Archived – Medication Errors Involving Reminyl and Amaryl – Janssen-Ortho Inc. and Aventis Pharma Inc.
… Images This is duplicated text of a letter from Janssen-Ortho Inc. & Aventis Pharma Inc. Contact the company … Care Professional: Please be aware of the following: Janssen-Ortho Inc. and Aventis Pharma Inc. (collectively, … Directorate at the following addresses: Janssen-Ortho Inc. 19 Green Belt Drive Toronto, OntarioM3C 1L9 Call toll-free at …
AlertHealth professional risk communication | 2004-12-21
Archived – Medication Errors Involving Reminyl and Amaryl –Janssen-Ortho Inc. and Aventis Pharma Inc.
… Images This is duplicated text of a letter from Janssen-Ortho Inc. & Aventis Pharma Inc. Contact the company … ® Dear Pharmacist: Please be aware of the following: Janssen-Ortho Inc. and Aventis Pharma Inc. (collectively, … Directorate at the following addresses: Janssen-Ortho Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 Call toll-free …
AlertHealth professional risk communication | 2004-12-21
Archived – New Safety Information Regarding Intelence (etravirine) and Severe Skin and Hypersensitivity Reactions – For the Public
… Starting date: October 19, 2009 Posting date: October 19, 2009 Type of … is duplicated text of a letter from Tibotec, a division of Janssen-Ortho Inc . Contact the company for a copy of any … Severe Skin and Allergic Reactions Tibotec, a division of Janssen-Ortho Inc. ("Tibotec"), in collaboration with Health …
AlertHealth professional risk communication | 2009-10-19
Archived – Important Drug Safety Information: Risperdal (Risperidone) and Cerebrovascular Adverse Events in Placebo-Controlled Dementia Trials – Janssen-Ortho Inc.
… RA-17000390 This is duplicated text of a letter from Janssen-Ortho Inc. Contact the company for a copy of any … Dementia Trials Dear Healthcare Professional: Janssen-Ortho Inc., following discussions with Health Canada, … USA-63 1% (5/462) 1% (2/163) BEL-14 0% (0/20) 0% (0/19) Total 4% (29/764) 2% (7/466) Four patients died in the …
AlertHealth professional risk communication | 2002-10-11
Archived – Medication Errors Involving REMINYL and AMARYL® – Janssen-Ortho Inc. and Aventis Pharma Inc.
… RA-19000210 This is duplicated text of a letter from Janssen-Ortho Inc. and Aventis Pharma Inc. Contact the … and AMARYL ® (glimepiride). Toronto, December 21, 2004 - Janssen-Ortho Inc. and Aventis Pharma Inc., (collectively, … Canada at the following addresses: Janssen-Ortho Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 Or call toll …
AlertHealth professional risk communication | 2004-12-21
Archived – Updated Safety Information Announced in Canada for Patients Taking TOPAMAX (Topiramate) Regarding Higher than Normal Blood Acid Levels – Janssen-Ortho Inc. – For the Public
… RA-19000220 This is duplicated text of a letter from Janssen-Ortho Inc. Contact the company for a copy of any … than Normal Blood Acid Levels Toronto, January 20, 2004 - Janssen-Ortho, following discussions with Health Canada, is … ensure that they are aware of this new safety information. Janssen-Ortho is working with Health Canada to update the …
AlertHealth professional risk communication | 2004-01-26